Tyrian Diagnostics Limited
Tyrian is an Australian company which develops and commercialises rapid point-of- care (PoC) or point-of-need (PoN) diagnostics for both clinical and non-clinical applications. Tyrian has developed an innovative and proprietary diagnostic test platform, DiagnostIQ™. The DiagnostIQ™ platform comprises a patented disposable test device which can be used alone or together with the DiagnostIQ™ Reader for various applications. DiagnostIQ™ is used for the development of diagnostic tests where accurate and time critical results are required to determine action to be taken at the PoC (human and veterinary tests) or PoN (agricultural and environmental tests). Tyrian also has expertise in discovering and developing biomarkers of disease as targets for diagnostic tests, particularly in respiratory and infectious diseases. The Company’s longer term plan is to exploit its intellectual property and expertise in this area through developing and partnering higher value proprietary clinical diagnostics. Tyrian’s business objective is to generate recurring revenues from a portfolio of rapid PoC and PoN diagnostic products. The Company's strategy is to deliver near term revenues through commercialisation of clinical and agricultural products by partnering with groups that have validated test content for implementation onto its patented DiagnostIQ™ platform. Longer term, Tyrian intends to develop higher value proprietary products for human health, particularly in the field of respiratory and infectious diseases. Tyrian’s product pipeline currently comprises the following applications:
- A test for wheat quality – ReadRite® Alpha Amylase – marketed by Bayer CropScience AG
- A second crop quality test with Bayer that is expected to be ready for market launch in 2010
- A point-of-care test for active TB at feasibility stage, in collaboration with US-based company BD
Number of employees: 25
Main business focus/
Listing by sector:
- AgBio - Plant
- Allergy & Respiratory
- Infectious Diseases
Our business strategy is to develop diagnostic products where convenient and time critical results are required at point-of-need or point-of-care. Tyrian’s patented DiagnostIQ™ platform provides an advantage over other similar technologies to provide fast and accurate results using crude samples in a simple-to-use and cost-effective format. The versatility of the product provides a competitive edge as it can be used to develop a variety of applications from clinical point-of-care settings (hospitals, home diagnosis, etc) to in-field applications such as agricultural testing.
Tyrian has sought patent protection in the major industrial jurisdictions for the various components of the DiagnostIQ™ platform, and as a result of this strategy, Tyrian has acquired rights to a significant patent portfolio. Tyrian is also seeking further protection for its biomarkers for use as targets for diagnostic tests particularly in respiratory and infectious diseases, as well as a range of processing methods which facilitate immunoassay detection of analytes from a variety of diagnostic samples including sputum.
Tyrian is pursuing partnering opportunities to expedite the development and commercialisation of new DiagnostIQ™ products.
|Contact person||Jenny Harry|
|Job Title||CEO & Managing Director|
|Address||Unit 1/35-41 Waterloo Road|
|State||New South Wales|
|Phone||+61 2 8877 8947|
|Fax||+61 2 9889 1805|